TSE:CPH Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free CPH Stock Alerts C$8.69 -0.13 (-1.47%) (As of 05/17/2024 ET) Add Compare Share Share Today's RangeC$8.59▼C$8.8150-Day RangeC$7.10▼C$9.5052-Week RangeC$3.30▼C$10.33Volume21,454 shsAverage Volume38,021 shsMarket CapitalizationC$209.52 millionP/E Ratio7.90Dividend YieldN/APrice TargetC$8.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlines Get Cipher Pharmaceuticals alerts: Email Address Cipher Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside0.7% UpsideC$8.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.33Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.23 out of 5 stars 1.3 Analyst's Opinion Consensus RatingCipher Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCipher Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Cipher Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CPH. Previous Next 0.0 Dividend Strength Dividend YieldCipher Pharmaceuticals does not currently pay a dividend.Dividend GrowthCipher Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CPH. Previous Next 0.9 News and Social Media Coverage News SentimentCipher Pharmaceuticals has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cipher Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cipher Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders44.51% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.12% of the stock of Cipher Pharmaceuticals is held by institutions.Read more about Cipher Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cipher Pharmaceuticals is 7.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Cipher Pharmaceuticals is 7.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 154.70.Price to Book Value per Share RatioCipher Pharmaceuticals has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cipher Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.Get the name and ticker symbol for free - just click here. About Cipher Pharmaceuticals Stock (TSE:CPH)Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.Read More CPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPH Stock News HeadlinesMay 15, 2024 | americanbankingnews.comCipher Pharmaceuticals (TSE:CPH) Stock Rating Lowered by Stifel NicolausMay 13, 2024 | finance.yahoo.comCipher Pharmaceuticals Downgraded to Hold at Stifel GMP Following Share-Price Gains; Price Target Raised to C$9.50April 28, 2024 | theglobeandmail.comCipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)April 27, 2024 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Friday (CPH)April 3, 2024 | ca.finance.yahoo.comStocks in play: Cipher PharmaceuticalsMarch 28, 2024 | theglobeandmail.comCipher Pharmaceuticals: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CPH)March 17, 2024 | seekingalpha.comCipher Pharmaceuticals (CPHRF) Q4 2023 Earnings Call TranscriptMarch 17, 2024 | investing.comEarnings call: Cipher Pharmaceuticals outlines growth and financialsJanuary 5, 2024 | morningstar.comCipher Pharmaceuticals Inc CPHJanuary 3, 2024 | finance.yahoo.comCipher Pharmaceuticals Inc (PHE.MU)November 24, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Change of AuditorNovember 24, 2023 | benzinga.comCipher Pharmaceuticals Stock (OTC:CPHRF) Dividends: History, Yield and DatesNovember 15, 2023 | finance.yahoo.comCipher Pharmaceuticals Inc.'s (TSE:CPH) 23% gain last week benefited both individual investors who own 56% as well as insidersOctober 27, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference CallSeptember 5, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian DollarsAugust 10, 2023 | finance.yahoo.comCipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in MexicoJuly 28, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference CallJuly 5, 2023 | finance.yahoo.comCipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European UnionJune 21, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Results of Annual and Special Meeting of ShareholdersMay 4, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q1 2023 Earnings Release and Conference CallApril 26, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Tuesday (CPH)April 20, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Thursday (CPH)April 18, 2023 | finanznachrichten.deBloom Burton & Co. Inc.: Cipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 18, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Tuesday (CPH)April 18, 2023 | finance.yahoo.comCipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceSee More Headlines Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/18/2024Next Earnings (Estimated)8/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CPH Previous SymbolTSE:DND CUSIPN/A CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price TargetC$8.75 High Stock Price TargetC$9.50 Low Stock Price TargetC$8.00 Potential Upside/Downside+0.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C$1.10 Trailing P/E Ratio7.90 Forward P/E Ratio13.91 P/E GrowthN/ANet IncomeC$20.38 million Net Margins96.32% Pretax MarginN/A Return on Equity28.19% Return on Assets8.06% Debt Debt-to-Equity Ratio0.44 Current Ratio9.19 Quick Ratio2.67 Sales & Book Value Annual SalesC$21.16 million Price / Sales9.90 Cash FlowC$2.46 per share Price / Cash Flow3.53 Book ValueC$3.36 per share Price / Book2.59Miscellaneous Outstanding Shares24,110,000Free FloatN/AMarket CapC$209.52 million OptionableNot Optionable Beta1.04 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Craig J. MullInterim CEO & Chairman of the BoardMr. Bryan JacobsChief Financial OfficerDr. Diane GajewczykVice President of Scientific & Medical AffairsMr. Emilio PrestiDirector of Sales & MarketingKey CompetitorsRIV CapitalTSE:RIVCardiol TherapeuticsTSE:CRDLLeaf MobileTSE:LEAFICC LabsCVE:ICCESSA PharmaCVE:EPIView All Competitors CPH Stock Analysis - Frequently Asked Questions Should I buy or sell Cipher Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CPH shares. View CPH analyst ratings or view top-rated stocks. What is Cipher Pharmaceuticals' stock price target for 2024? 2 Wall Street analysts have issued twelve-month price targets for Cipher Pharmaceuticals' shares. Their CPH share price targets range from C$8.00 to C$9.50. On average, they expect the company's stock price to reach C$8.75 in the next twelve months. This suggests a possible upside of 0.7% from the stock's current price. View analysts price targets for CPH or view top-rated stocks among Wall Street analysts. How have CPH shares performed in 2024? Cipher Pharmaceuticals' stock was trading at C$5.54 at the start of the year. Since then, CPH stock has increased by 56.9% and is now trading at C$8.69. View the best growth stocks for 2024 here. When is Cipher Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CPH earnings forecast. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (TSE:CPH) announced its earnings results on Thursday, March, 14th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.15 by $0.26. The firm had revenue of $6.70 million for the quarter, compared to analysts' expectations of $7.31 million. Cipher Pharmaceuticals had a trailing twelve-month return on equity of 28.19% and a net margin of 96.32%. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Catalyst Biosciences (CBIO), Crescent Point Energy (CPG) and Enbridge (ENB). How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:CPH) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlacePOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.